SGB is a deceptively simple procedure with an ambitious target. It involves injecting a small volume of local anesthetic around the cervicothoracic sympathetic chain, a bundle of nerve cells in the neck that forms part of the body’s fight-or-flight machinery. The idea is that chronic insomnia coexisting with anxiety is sustained partly by sympathetic overdrive: racing heart, mental vigilance, sleep-related worry. By transiently damping this output, the block may rebalance autonomic tone and lower the physiological arousal that undermines both sleep and the confidence to taper medication. The procedure has previously been investigated for posttraumatic stress symptoms, anxiety, and sleep disturbance, but most studies have measured symptom scales rather than the outcome that matters most for long-term safety: whether patients actually take fewer hypnotic drugs.

The research team screened 420 medical records from January 2022 through December 2025 and assembled two carefully matched groups of 80 adults each, all of whom had chronic insomnia lasting at least three months, documented anxiety symptoms, and ongoing use of at least one hypnotic or sedative medication. The treated group completed a standardized four-session SGB pathway, delivered once daily on four consecutive days with left and right sides alternated. Each procedure was performed under real-time ultrasound guidance at the C7 vertebral level, with a 22-gauge needle advanced to the prevertebral fascial plane in front of the longus colli muscle before 5 milliliters of 2% lidocaine was injected. Successful blockade was confirmed by the appearance of Horner signs, the expected constellation of eyelid drooping and pupillary constriction indicating that the sympathetic chain had indeed been anesthetized. Controls were drawn from contemporaneous routine care using calendar-time risk-set sampling, with each control encounter falling in the same month and within two weeks of the corresponding treated patient’s index date.

The primary outcome was deliberately pragmatic: at one month, a patient had to hit at least one of three medication-reduction milestones, namely a 50% or greater drop in an operational medication-burden score, a transition from combination therapy to a single agent, or complete discontinuation maintained for at least two weeks. The results were striking. Thirty-two of 80 patients in the SGB-based pathway, or 40%, met the composite outcome, versus 12 of 80 routine-care patients, or 15%. That crude difference of 25 percentage points survived adjustment. A parsimonious robust Poisson model, restricted to age, sex, baseline medication burden, and baseline medication count because only 44 outcome events were available, yielded an adjusted risk ratio of 2.43. Marginal standardization, which predicts each participant’s outcome under both exposure states while preserving the observed covariate distribution, put the adjusted risks at 38.0% versus 16.7%, an absolute difference of about 21 percentage points.

Digging into the components revealed where the signal truly lived. The strongest and most consistent association was with substantial dose reduction: 33.8% of SGB-pathway patients achieved at least a 50% cut in medication burden compared with 11.2% of controls, an adjusted risk ratio of 2.77. Class-specific analyses told a compatible story. Among baseline benzodiazepine users, doses expressed as approximate diazepam equivalents fell by half or more in 28.2% of treated patients versus 8.9% of controls. Z-drug reductions, quantified in World Health Organization defined daily dose units, were directionally similar but less statistically precise. By contrast, transition to monotherapy and complete discontinuation were numerically more frequent in the SGB group but came with wide confidence intervals that spanned the null. In plain terms, the pathway appears to help patients take much less medication, but the evidence that it helps them stop entirely remains inconclusive.

The benefits appeared to persist. At three months, a maintained response was recorded in 31.3% of treated patients with follow-up versus 13.6% of controls, and the association held when missing follow-up was conservatively counted as failure and when inverse-probability-of-censoring weighting was applied. The treated group also showed greater standardized improvement in sleep, anxiety, and depression symptoms, though the heterogeneous symptom scales make these supportive findings harder to interpret. Safety data were reassuring within the limits of retrospective documentation: across 320 procedures, 15 patients, or 18.8%, experienced a recorded procedure-related event, all mild or moderate. Transient dizziness, hoarseness, puncture-site pain, and two vasovagal reactions resolved with rest, observation, oxygen, or fluids, and no serious event was recorded.

What sets this study apart methodologically is the battery of sensitivity analyses. The authors deployed propensity-score matching, overlap weighting, and trimmed stabilized inverse probability weighting, each targeting a different population average, and every approach converged on an adjusted risk ratio between roughly 2.3 and 2.7 with absolute risk differences between 18 and 23 percentage points per 100 patients. One thousand bootstrap resamples converged, and adding potential confounders such as depression severity, antidepressant use, thyroid disease, or body mass index one at a time did not reverse the treatment coefficient. Firth penalized logistic regression confirmed stability in the face of sparse events, a well-known pitfall of standard logistic regression when outcomes are rare.

Yet the authors are refreshingly candid about what the design cannot prove. Because treatment allocation was nonrandomized, the results speak to an SGB-containing care pathway, not to an independent causal effect of the injection itself. Baseline imbalances were real: treated patients had more severe depression, far more antidepressant use, and slightly lower starting medication burdens. Clinician-directed taper plans were documented somewhat more often in the SGB pathway, raising the possibility that physicians simply encouraged tapering more intensively after the procedure. And the authors raise a subtle point that plagues many procedural interventions: receiving an invasive treatment may itself boost expectancy, perceived treatment intensity, and willingness to reduce medication, independently of any physiological effect of sympathetic blockade. No sham-controlled comparison was possible, and treatment expectations were not measured.

The study also grapples honestly with its measurement choices. Benzodiazepine doses were converted to approximate diazepam equivalents using published guidance, while Z-drugs were handled in defined daily dose units, and the broader cross-class burden score was explicitly labeled exploratory rather than a validated pharmacological scale. Missingness, though modest, was linked to baseline medication burden, and the statistical corrections for it rest on unverifiable assumptions. Propensity-score distributions overlapped imperfectly, and residual imbalance persisted even after matching and weighting, reminders that observational data can narrow but never eliminate the fog of confounding.

For now, the take-home message is cautiously intriguing rather than practice-changing. In a clinical landscape where guidelines recommend cognitive behavioral therapy for insomnia and gradual, patient-centered tapering but where access to CBT-I is often limited and anxiety makes deprescribing fragile, a four-session ultrasound-guided procedure associated with roughly 20 additional medication reductions per 100 treated patients warrants serious attention. The researchers call for prospective multicenter trials with randomized or strong quasi-experimental allocation, standardized de-prescribing protocols, class-specific dose measures, autonomic biomarkers, and, crucially, sham-controlled designs that can separate the physiology of sympathetic blockade from the psychology of undergoing a procedure. Until then, the stellate ganglion remains a tantalizing but unproven ally in one of sleep medicine’s hardest problems: helping patients finally put down the pill bottle.

Subject of Research: Association of stellate ganglion block-based care with hypnotic medication reduction in chronic insomnia with anxiety symptoms

Article Title: Association of a stellate ganglion block-based care pathway with hypnotic medication reduction in chronic insomnia with anxiety symptoms: a real-world retrospective cohort study

Article References: Wang, D., Wang, X., Wang, W., & Wang, Y. (2026). Association of a stellate ganglion block-based care pathway with hypnotic medication reduction in chronic insomnia with anxiety symptoms: a real-world retrospective cohort study. Frontiers in Sleep, 5, Article 1923070. https://doi.org/10.3389/frsle.2026.1923070

Image Credits: AI Generated

DOI: 10.3389/frsle.2026.1923070

Keywords: stellate ganglion block, chronic insomnia, anxiety symptoms, hypnotic deprescribing, benzodiazepines, Z-drugs, retrospective cohort study, propensity score, sleep medicine, real-world evidence, autonomic nervous system, Association

TaVNS is a non-invasive form of vagus nerve stimulation. Instead of an implanted electrode, it delivers gentle electrical pulses through the skin of the outer ear, specifically targeting the auricular branch of the vagus nerve, the only peripheral branch of this cranial nerve that reaches the body surface. From there, sensory signals travel to the nucleus tractus solitarius in the brainstem and cascade through autonomic and neuromodulatory systems, including the locus coeruleus and other arousal-related nuclei. Because the vagus nerve is a major conduit of the parasympathetic, rest-and-digest branch of the autonomic nervous system, researchers have long hypothesized that stimulating it could shift the body’s balance away from hyperarousal, the state of physiological vigilance that many insomnia researchers consider the core dysfunction of the disorder.

Most previous mechanistic studies of taVNS in insomnia have concentrated on the cortex and limbic system, examining regions such as the default mode network, the insula, and emotional regulation circuits. What has been missing, the authors argue, is attention to the hypothalamus, and in particular the lateral hypothalamus. This small, deep structure is not a passive relay; it is a master switch for arousal. It contains populations of neurons producing orexin, also known as hypocretin, the neuropeptide whose loss causes narcolepsy, as well as neurons producing melanin-concentrating hormone, which is involved in sleep regulation. The lateral hypothalamus also projects widely to cortical and subcortical networks that govern attention, reward, and autonomic tone. If taVNS genuinely works by modulating arousal systems, the lateral hypothalamus should sit at the center of the story, yet until now its role had barely been probed.

To fill that gap, the research team, led by Jingwen Zhang, Yue Zhang, Xiyong Dai, and colleagues at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, enrolled seventy patients with chronic insomnia and randomized them to receive either real or sham taVNS. The trial was registered with the Chinese Clinical Trial Registry in April 2019 and approved by the institution’s ethics committee, and all participants gave written informed consent. Before and after the treatment period, patients underwent resting-state functional MRI scans and completed standardized clinical instruments: the Pittsburgh Sleep Quality Index, the Insomnia Severity Index, and the Self-Rating Anxiety Scale. Using the bilateral lateral hypothalamus as seed regions, the investigators computed whole-brain functional connectivity, a measure of how synchronously activity in different brain regions fluctuates over time, and compared how these connectivity patterns changed between the real and sham stimulation groups.

The clinical results were clear. Compared with sham stimulation, real taVNS produced significantly greater reductions in PSQI, ISI, and anxiety scores, indicating improvements in sleep quality, insomnia severity, and anxiety symptoms. But the neuroimaging findings are what give the study its mechanistic teeth. Real stimulation strengthened functional connectivity between the left lateral hypothalamus and two regions: the right cerebellar Crus2 and the right precuneus. At the same time, it weakened connectivity between the left lateral hypothalamus and the left insula and the left orbital frontal cortex. Each of these changes is interpretable in the context of sleep and arousal neuroscience, and together they sketch a coherent picture of how peripheral nerve stimulation might reach deep into the brain’s arousal machinery.

Consider the strengthened connections first. The precuneus is a hub of the default mode network, the set of regions most active during rest and internally directed thought, and it is intimately involved in the transition between wakefulness and sleep. Cerebellar Crus2, meanwhile, has been repeatedly implicated in sleep-disordered networks and in the regulation of autonomic function. The finding that increased connectivity between the left lateral hypothalamus and Crus2 correlated with the degree of clinical improvement, with a correlation coefficient of -0.473 and a p-value of 0.011, is particularly striking, because it links a specific circuit change to a specific symptom outcome: the more this connection strengthened, the more patients’ sleep quality scores improved. The weakened connections tell a complementary story. The insula is central to interoception, the brain’s monitoring of internal bodily states, and hyperactive insula connectivity is often interpreted as a neural signature of heightened bodily awareness and arousal in insomnia. The orbital frontal cortex participates in valuation and emotional regulation. Reducing lateral hypothalamic coupling with these regions may reflect a dialing down of the vigilance and emotional reactivity that keep insomnia sufferers lying awake.

Beyond the group-level findings, the study ventured into more speculative but potentially transformative territory: predicting treatment response before it happens. The researchers built a whole-brain, voxel-wise support vector regression model, a machine learning approach that maps patterns of brain connectivity onto a continuous outcome, in this case the change in PSQI score within the real taVNS group. To keep the model honest, they used ReliefF feature selection to identify the most informative connectivity features, trained on seventy percent of the data and tested on the remaining thirty percent, and evaluated significance with 5,000 permutation tests. The single most predictive baseline feature involved the gyrus rectus, a medial prefrontal region adjacent to the orbital surface that is connected to limbic and autonomic circuits. The model achieved a correlation of 0.662 between predicted and observed improvement in the test set, with a p-value of 0.0264 and a permutation-corrected p-value of 0.0142.

That result, if it holds up, points toward a future in which a brief pretreatment brain scan could tell clinicians which insomnia patients are likely to respond to taVNS, sparing others the time and expense of an ineffective course. The authors are careful, however, to frame this as exploratory. The sample size was modest, the prediction analysis was conducted within the real stimulation group only, and the whole-brain machine learning approach carries well-known risks of overfitting even with permutation testing. The researchers explicitly state that these findings require validation in larger, independent cohorts and do not yet support clinical application. That caution is appropriate, and it is a welcome contrast to the hype that often surrounds brain stimulation and machine learning in popular coverage.

Nevertheless, the study’s significance is hard to overstate. It is among the first to demonstrate that a non-invasive, ear-based stimulation technique can measurably alter the functional connectivity of the lateral hypothalamus in humans, and that these alterations track with symptom improvement. It reframes taVNS not as a vague relaxation technique but as a targeted intervention on defined arousal circuitry, and it offers a candidate biomarker, lateral hypothalamic-cerebellar connectivity, for tracking treatment effects. For a disorder that is usually managed with medication or cognitive behavioral therapy, the prospect of a device-based, mechanistically grounded alternative is genuinely exciting.

Much work remains. Future studies will need larger and more diverse samples, longer follow-up periods to test whether the connectivity changes and clinical benefits persist, and designs that can disentangle taVNS effects from placebo responses more finely. Researchers will also want to determine optimal stimulation parameters, since frequency, intensity, and session duration all plausibly shape which circuits are engaged. But the core message of this trial stands on its own: the path to better sleep for chronic insomniacs may run through a small patch of skin on the ear, a wandering cranial nerve, and the ancient hypothalamic machinery that decides whether the brain stays awake or lets go into sleep.

Subject of Research: Effects of transcutaneous auricular vagus nerve stimulation on lateral hypothalamic functional connectivity in chronic insomnia

Article Title: Effects of transcutaneous auricular vagus nerve stimulation on lateral hypothalamic functional connectivity in chronic insomnia: a randomized, sham-controlled fMRI study with exploratory prediction of treatment response

Article References: Zhang, J., zhang, Y., Dai, X., Mai, R., Xu, B., & Liu, B. (2026). Effects of transcutaneous auricular vagus nerve stimulation on lateral hypothalamic functional connectivity in chronic insomnia: a randomized, sham-controlled fMRI study with exploratory prediction of treatment response. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08708-4

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08708-4

Keywords: chronic insomnia, taVNS, vagus nerve stimulation, lateral hypothalamus, functional connectivity, fMRI, sleep-wake regulation, machine learning, support vector regression, precuneus, cerebellum, treatment response prediction